AbstrAct: Contemporary metallic drug-eluting stents are associated with very good 1-year outcomes but an ongoing risk of stent-related adverse events (thrombosis, myocardial infarction, restenosis) after 1 year. The pathogenesis of these very late events is likely related to the permanent presence of the metal stent frame or polymer. Bioresorbable scaffolds have been developed to provide drug delivery and mechanical support functions similar to metallic drug-eluting stents, followed by complete resorption with recovery of more normal vascular structure and function, potentially improving very late clinical outcomes. A first-generation bioresorbable scaffold has been demonstrated to be noninferior to a contemporary metallic drug-eluting stents for overall 1-year patient-oriented and device-oriented outcomes. Increased rates of scaffold thrombosis and target vessel-related myocardial infarction were noted that may be mitigated by improved patient and lesion selection, procedural technique, and device iteration. Large-scale, randomized, clinical trials are ongoing to determine the long-term relative efficacy and safety of bioresorbable scaffolds compared with current metallic drug-eluting stents.
STATE OF THE ART
Fully bioresorbable scaffolds (BRSs), composed of naturally occurring and synthetic biodegradable polymers (Table I in the online-only Data Supplement), 7 are intended to provide mechanical support and drug delivery functions similar to those of metallic DES early (within 6-12 months) after percutaneous coronary intervention, followed by progressive bioresorption, resulting in recovery of cyclic pulsatility and vasoregulation ( Figure 1) . Furthermore, complete resorption of BRSs over several years is accompanied by return of adaptive vascular remodeling (ability of the vessel to enlarge to accommodate plaque growth to preserve lumen dimensions), a phenomenon not possible with a permanent metallic stent. Thus, BRSs were developed to have short-term (1-year) outcomes similar to those of contemporary metallic DES, with improved long-term outcomes (Table 1) . BRSs may be particularly useful in younger patients with extended life expectancy and in patients with acute coronary syndromes in whom metallic DES heal poorly. 4 Additional practical benefits of late device bioresorption include unjailing covered side branches, avoiding a permanent "full metal jacket" when treating diffuse disease (restoring late bypass grafting options), allowing treatment of in-stent restenosis without additional space-occupying metal stent layers, compatibility with noninvasive imaging (avoidance of blooming artifacts), and personal patient preference to avoid permanent implants. However, current BRSs have limitations compared with contemporary metallic DES that should be appreciated (Table 1) .
BRSs include polymeric and metallic (magnesium or iron alloy) platforms (Table 2) , which may vary greatly. Here, we provide an overview of the design goals for BRSs, focusing on the 3 most extensively studied devices: the poly-l-lactic acid (PLLA)-based Absorb Bioresorbable Vascular Scaffold (BVS; Abbott Vascular) and DESolve (Elixir Medical) and the magnesium-based DREAMS (Biotronik) scaffold.
At this point, we would like to draw a distinction between BRSs and bioabsorbable polymer stents such as SYNERGY (Boston Scientific Corp) and BioMatrix (Biosensors Inc), which are metallic stents that elute an antiproliferative drug (everolimus or biolimus, respectively) from a bioabsorbable polymer applied to the abluminal surface. The drug is released early, and the polymer is resorbed by 4 months (SYNERGY) or 9 months (BioMatrix), leaving behind a bare metal stent. With BRS technology, none of the stent components (drug, polymer, or scaffold) are left behind.
DeSigN PRiNCiPleS foR BRSS: PhaSeS of fuNCtioNality
BRSs address 3 overlapping mechanistic phases of functionality that occur successively over several years after device implantation: revascularization, restoration, and resorption ( Figure 1 ). The timing of these phases varies with differing scaffolds.
Revascularization
This phase involves alleviation of an ischemia-producing coronary stenosis, similar to metallic DES. To compensate for reduced mechanical strength of most bioresorbable materials relative to metal alloys, the strut width and thickness of current BRSs have been increased. Conversely, polymeric BRSs have greater flexibility and conformability with less geometric distortion and greater maintenance of normal vessel curvature than metallic DES, which, by improving flow dynamics and shear stress distribution, may reduce platelet deposition, neoatherosclerosis, and device fracture that commonly manifest as very late restenosis or thrombosis.
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Restoration
This phase is characterized by a progressive reduction in the molecular weight of the device followed by mass loss. With polymeric scaffolds, molecular weight loss occurs by hydrolysis and depolymerization, followed by metabolism of lactate into carbon dioxide and water via the Krebs cycle, with progressive mass loss. 7, 12 Most polymers exhibit bulk erosion, with the surface and interior degrading at uniform rates, a process affected mainly by water concentration and temperature. In contrast, magnesium scaffolds absorb by surface erosion (corrosion) through a series of oxidation-reduction reactions (also water dependent), resulting in magnesium hydroxide and magnesium cations that are renally excreted. 13 With both polymeric and metallic scaffolds, the loss of radial rigidity and mechanical constraint is followed by recovery in cyclic strain and pulsatility, 14, 15 which are associated with improved endothelial nitric oxide synthase and extracellular matrix production, and a normal, contractile phenotype of vascular smooth muscle cells. 16, 17 Recovery in vasomotor responsiveness to acetylcholine, methergine, and nitroglycerine has been demonstrated during the restoration phase. 18 Both the Absorb polymeric scaffold and the DREAMS magnesium scaffold have demonstrated freedom from mechanical restraint and restored vasomotion in response to acetylcholine and nitrates at 6 to 12 months after percutaneous coronary intervention. 19 
Resorption
Complete BRS resorption is necessary for full recovery of vascular structure and function and may require several years with current bioresorbable devices. Se-rial intravascular imaging of Absorb has demonstrated late lumen preservation or gain in preclinical models and humans. 14, [20] [21] [22] [23] Increases in internal and external elastic lamina areas and vessel lumen area are evident within 12 to 18 months after Absorb deployment in the porcine model. 14, 21 Similarly, serial intravascular ultrasound and optical coherence tomography (OCT) imaging in humans have demonstrated increased vessel lumen areas between 1 and 5 years after Absorb implantation as a result of both positive vessel remodeling and plaque regression. 18, 20, 22 Lumen areas decrease for 6 months after Absorb implantation, followed by stabilization and enlargement. 20 These observations differ from those for metallic DES, for which mean/minimum lumen diameters decrease over time as a result of plaque growth within a fixed metal frame. 6 Coincident with absorption, BVS polymeric struts are replaced by collagen and vascular smooth muscle cells (neomedia), which retract over time, normalizing the lumen (Figure 2 ). 22 Enlarging luminal dimensions promote shear stress normalization and may have salutary effects on endothelial function and the prevention of atherosclerosis. Radiofrequency intravascular ultrasound has demonstrated a progressive increase in fibrous content and reduction in necrotic core consistent with plaque stabilization and regression over time after Absorb implantation. 18, 20, 23 In addition, everolimus (eluted by Absorb) has antiproliferative, anti-inflammatory, and plaque-stabilizing properties by promoting macrophage autophagy and clearance. 24 The connective tissue layer that follows strut resorption effectively seals lipid-rich plaques ( Figure I in the online-only Data Supplement) and may prevent subsequent rupture or erosion. 22, 23 These salutary vascular responses after Absorb implantation contrast with the relative lack of healing with metallic DES after deployment in fibroatheromas. 25 figure 1. Phases of bioresorbable scaffold (BRS) functionality.
The 3 phases of BRS functionality include mechanical support and drug delivery functions during the revascularization phase; the loss of radial rigidity and mechanical restraint during the restoration phase, during which cyclic pulsatility and vasomotion return; and resorption caused by mass loss with return of adaptive vascular remodeling responses. The time course for phases/changes noted on the top is specific for the Absorb Bioresorbable Vascular Scaffold. Molecular weight starts to decrease immediately after implantation, and drug elution is almost complete at 3 months. Radial support decreases at ≈6 months and is minimal at 12 months. Representative histology and optical coherence tomography (OCT) images are from Yucatan swine. On OCT, the struts are sequestered from the lumen by fibromuscular neointima at 3 to 6 months. At 24 months, with progressive mass loss, the strut footprints begin to be replaced by provisional matrix (histology) while still discernible as black cores (OCT). At 36 months, mass loss is complete, and infiltration of connective tissue into strut voids makes the struts invisible on OCT between 36 and 48 months.
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The Absorb BVS is made up of a balloon-expandable PLLA scaffold (strut thickness, ≈150 µm) with a bioresorbable, conformal poly d,l-lactic acid coating (≈7 µm thick) that elutes everolimus with systemic elution kinetics similar to the Xience metallic DES ( Figure II in the online-only Data Supplement). 26, 27 Two platinum markers at each end enable radiographic visualization.
Specific properties related to PLLA and the manufacturing process influence the mechanical properties of the scaffold. The lower tensile strength, reduced stiffness, and reduced ductility (ability to deform under tensile stress without breaking) of PLLA versus metal require increased strut thickness to achieve adequate structural support and limit Absorb distensibility to ≈0.7 mm beyond nominal diameter, necessitating careful sizing and implantation technique to avoid malapposition, underexpansion, and strut fracture. 28 Although bench test results suggest comparable radial strength for BVS and the metallic Xience DES, quantitative coronary angiographic (QCA) analyses in most randomized trials 9, [29] [30] [31] [32] have demonstrated less acute gain, a smaller minimum lumen diameter, and greater residual stenosis after BVS implantation, possibly reflecting greater in vivo acute recoil (as also suggested by video densitometry), particularly in fibrocalcific lesions. 33 However, a systematic measurement difference in QCA edge detection between the thicker radiolucent BVS struts and the thinner, more radiodense metallic DES struts has been described that may underlie these differences in angiographic measures (Patrick Serruys, unpublished observations).
absorb Clinical experience
The registry and randomized trial experience with BVS is extensive (Table II in the online-only Data Supplement). Serial intravascular imaging through 5 years in 101 patients has provided objective characterization of Absorb scaffold resorption and coronary arterial healing in humans. 18, 20, 22 Return of vasomotion and increased scaffold/lumen areas with positive adaptive remodeling have been noted at and beyond 1 year, with complete scaffold resorption by 3 years. 20 There have been 6 completed randomized trials of Absorb BVS versus Xience DES, with follow-up duration reported between 6 and 24 months. In the largest trial (ABSORB III, n=2008), 32 Absorb was noninferior to Xience for the primary end point of TLF at 1 year (7.8% for Absorb, 6.1% for Xience; difference, 1.7%; 95% confidence interval, −0.5 to 3.9; P noninferiority =0.007, P superiority =0.16). Comparable overall event rates between BVS and Xience were also reported in a patient-level meta-analysis involving 3389 patients enrolled in the ABSORB II, ABSORB III, ABSORB Japan, and ABSORB China trials (Table 3) . 34 In this meta-analysis, the 1-year incidence of TVMI was increased with Absorb compared with Xience (relative risk, 1.45; 95% confidence interval, 1.02-2.07; P=0.04), in part as a result of a nonsignificant trend toward increased thrombosis (relative risk, 2.09; 95% confidence interval, 0.92-4.75; P=0.08). 34 No significant differences in periprocedural MI were observed with Absorb compared with Xience. 34 The comparable rates for most clinical events to 1 year with a first-generation BRS device compared with a state-of-the-art metallic DES are promising, especially because most physician-operators were inexperienced with the techniques required for optimal scaffold implantation. In ABSORB III and the patient-level ABSORB meta-analysis, rates of ischemia-driven target lesion revascularization, ischemia-driven target vessel revascularization, and all revascularization to 1 year were similar between BVS and Xience, demonstrating comparable efficacy. ,32 Before ABSORB III, lower rates of angina after BVS (versus Xience) were observed in a nonrandomized, propensitymatched comparison of patients from the ABSORB EX-TEND registry and SPIRIT IV trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and in the randomized ABSORB II trial.
9,26 These studies were not prospectively designed or powered for angina, however. In the larger ABSORB III trial, angina was prespecified and powered as a secondary end point, and no difference in 1-year angina was observed (18.3% for BVS versus 18.4% for Xience). However, in all of these studies, angina was site determined and classified as an adverse event without independent central adjudication. More definitive evaluation of whether there is a difference in angina between BVS and Xience awaits the 5000-patient randomized ABSORB IV trial, in which detailed study processes are in place to ensure patient blinding, prospective collection of symptom recurrence, antianginal medication use, and central adjudication of angina.
absorb BVS Scaffold thrombosis
In early registries, a signal was observed for greater scaffold thrombosis with Absorb compared with historical rates with contemporary DES. 35 In a study-level meta-analysis of 6 randomized trials (3738 randomized patients), Absorb was associated with a greater risk of definite/probable thrombosis than Xience (odds ratio, 1.99; 95% confidence interval, 1.00-3.98; P=0.05), with the highest risk in the subacute period (days 1-30) after implantation (odds ratio, 3.11; 95% confidence interval, 1.24-7.82; P=0.02). 36 Several observational studies 37 and a study-level meta-analysis 38 have subsequently suggested higher rates of early (≤30 days) thrombosis but similar rates of late (>30 days) thrombosis rates with Absorb compared with Xience.
Multiple factors may predispose to Absorb scaffold thrombosis ( Figure III in the online-only Data Supplement), [39] [40] [41] the most important of which appear to be lack of expansion, small minimum lumen diameter, and greater postprocedural percent diameter stenosis. AB-SORB III also identified very small target vessel diameter, diabetes mellitus, and early (<30 days) interruption of dual antiplatelet therapy as contributing factors. 32 In terms of the importance of vessel size, ≈19% of patients enrolled in ABSORB III had a target lesion with a reference vessel diameter <2.25 mm by QCA (corresponding to a visual estimate of <2.5 mm, which, by protocol, should have precluded enrollment). 32 BVS thrombosis within 1 year occurred in 4.6% of patients with very small target vessels compared with 1.5% with Xience, likely because of the greater space-occupying effect of the thicker, wider Absorb struts. 42 Conversely, 1-year rates of device thrombosis were lower and similar (0.9% versus 0.6%, respectively) among patients with target lesion QCA reference vessel diameters ≥2.25 mm (≈81% of all patients). Other ABSORB III clinical end points were similar between devices in vessels appropriate for enrollment (≥2.25 mm; Figure 3) . Similarly, in a real-world registry experience, a QCA postprocedural minimum lumen diameter <2.4 mm after deployment of the 2.5/3.0-mm scaffolds and maximum device footprint (abluminal strut surface area) >36% were associated with scaffold thrombosis. 43 The relationships of nominal BVS scaffold size to QCA maximum reference vessel diameter and to clinical outcomes were evaluated in a pooled patient-level analysis from 3 ABSORB studies. 44 Subjects with both proximal and distal maximum reference vessel diameters smaller than nominal scaffold size (scaffold oversize group) incurred higher rates of major cardiovascular events and TVMI than those in whom the proximal or distal maximum reference vessel diameter was larger than the scaffold (scaffold nonoversize group). Thus, careful attention to patient/lesion selection and optimal technique, including aggressive lesion preparation (1:1 balloon-artery ratio) with noncompliant balloons (or cutting/scoring balloons or atheroablation to improve lesion compliance), accurate vessel and device sizing (including avoiding very small vessels), routine noncompliant balloon high-pressure (≥16 atm.) postdilatation, and liberal use of intravascular imaging, may reduce scaffold thrombosis rates. 42, 43 Indeed, adoption of a BVS scaffold-specific deployment strategy, including optimal predilatation, scaffold:reference vessel diameter sizing, and high-pressure postdilatation, markedly reduced the incidence of scaffold thrombosis in a realworld registry experience. 43 There may also be mechanisms of device thrombosis specific to BRSs. Strut discontinuity with marked suppression of neointimal hyperplasia may result in prolapse of a scaffold segment into the vessel lumen (before absorption is complete), a phenomenon called intraluminal scaffold dismantling. Intraluminal scaffold dismantling has been associated with restenosis and thrombosis. 45, 46 The frequency of this phenomenon is undetermined.
long-term follow-up With absorb BVS
Clinical follow-up through 3 years in the ABSORB EX-TEND registry and 2 years in the ABSORB II trial demonstrates composite patient-oriented (all-cause death, all MI, or all revascularization) and device-oriented (TLF,
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cardiac death, TVMI, or ischemia-driven target lesion revascularization) event rates that appear to be comparable between Absorb BVS and Xience. 47, 48 An example of long-term follow-up after Absorb is shown in Figure 4 . 49 Whether Absorb improves long-term outcomes compared with Xience will be answered in the ongoing 5000-patient randomized ABSORB IV trial, powered to demonstrate superiority of Absorb for TLF between 1 and 5 years after implantation, the results of which are expected in 2020.
absorb in St-Segment-elevation Mi
The vascular healing responses of Absorb and Xience were evaluated in ST-segment-elevation MI (STEMI) in the TROFI II trial (Thrombus Aspiration on Flow Area in STEMI Patients: an Optical Frequency Domain Imaging Study). 50 OCT in 191 randomized patients at 6 months demonstrated high arterial healing scores [calculated as (percent intraluminal defect×4)+(percent malapposed and uncovered×3)+(percent uncovered×2)+(percent malapposed)] with both devices [Absorb, 1.74±2.38; Xience, 2.80±4.44; P noninferiority <0.001, P superiority =0.053 favoring Absorb (lower is better)]. 50 Absorb also had fewer uncovered and malapposed struts than Xience. Acute lumen gain by QCA was similar for both devices, in contrast to earlier studies in patients with stable coronary artery disease. STEMI may represent an ideal clinical scenario for use of Absorb because STEMI culprit lesions are frequently localized in proximal coronary segments with large reference vessel diameter and typically contain soft, lipid-rich necrotic core plaque, which may facilitate Absorb expansion. 51 TROFI II provides the basis for further investigation of Absorb BVS use in STEMI in 5000 randomized patients in the HORIZONS-ABSORB AMI trial (Harmonizing Outcomes With Revascularization, Stents and Absorb in AMI).
absorb Device iterations
A next-generation Absorb is under development, featuring substantially thinner struts (<100 μm), a lower profile, and a wider expansion range. This device is expected to enter human clinical studies in 2016 (Richard Rapoza, personal communication).
DeSolVe BRS
DESolve is a balloon-expandable, PLLA-based, multipolymeric scaffold (150-µm strut thickness) with platinum markers at each end for visualization. The first version of this device eluted the rapamycin analog myolimus, 52 whereas the current Conformité Europée-ne-marked version elutes novolimus (dose, 5 µm/mm scaffold length; 80% eluted within 1 month). 53, 54 Novel features of DESolve include (1) a self-expanding (selfcorrection) property that allows the device to passively increase in diameter by ≈0.3 mm within 20 to 60 minutes of deployment that has been attributed to a proprietary blend of polymers and processing technique, plus storage at 0 to 8°C; (2) a 95% reduction in molecular weight by 1 year, with complete absorption by 2 years; (3) adequate radial strength and vessel support for 3 to 4 months; and (4) high elasticity and ductility, which provide expansion to 5 mm without strut fracture (although hoop strength is substantially reduced at these diameters).
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figure 2. Differences in vascular healing between metal stents and absorb bioresorbable scaffolds.
Optical coherence tomography at midterm (6-12 months) and long term (2-5 years) after Absorb implantation demonstrates replacement of the thick polymeric struts by collagen and smooth muscle cells, with subsequent retraction and associated lumen preservation/enlargement during follow-up. Plaque sealing after Bioresorbable Vascular Scaffold implantation occurs by formation of a connective tissue neomedia after strut resorption. Conversely, the metallic stent constrains the vessel and allows only progressive lumen narrowing, with an increasing likelihood over time that in-stent neointimal tissue will convert to an unstable lipid-rich phenotype (neoatherosclerosis). Changes in plaque constituent components are represented. Adapted with permission from Karanasos et al. 22 Copyright © 2014, Elsevier, Ltd.
Table II in the online-only Data Supplement outlines studies with the different DESolve scaffolds. First human use with the myolimus-eluting DESolve in noncomplex lesions reported low late loss by QCA at 6 months (0.19±0.19-mm in-scaffold loss; 0.31±0.54-mm in-segment loss), acute scaffold recoil of 6.4%, and an increase in OCT mean scaffold area from after the procedure to 6 months (6.57±0.68 and 6.80±0.85 mm 2 , respectively). 51 More recently, in the DESolve NX single-arm study (n=122 noncomplex lesions), the novolimus-eluting DESolve demonstrated 6-month in-scaffold and in-segment QCA late loss of 0.20±0.32 and 0.21±0.31 mm, respectively, with 3.5% binary restenosis. In an OCT substudy (n=38), mean scaffold area increased from after the procedure to the 6-month follow-up (from 7.04±1.26 to 8.17±1.34 mm 2 ;
P<0.001).
53 Structural discontinuities were identified in 2 cases (5.3%); circumferentially misaligned struts that were fully encapsulated by neointimal tissue were present in 12 scaffolds (31.6%); and floating struts (intraluminal scaffold dismantling) were noted in 5 scaffolds (13.2%). Among 122 patients with successful implantation, major cardiovascular events occurred in 4 patients (3.3%) at 6 months and 9 patients (7.4%) at 24 months, including 1 probable stent thrombosis within 30 days. A typical case example with the DESolve scaffold is shown in Figure 5 .
DESolve has undergone several iterations through alterations in polymer processing, initially to 100-µm strut thickness, 54, 55 although current studies are using a de- The denominator in each cell is eligible patients (1-year follow-up or earlier event). BVS indicates Bioresorbable Vascular Scaffold; CI, confidence interval; CoCr EES, cobalt-chromium everolimus-eluting stent; ID-TLR, ischemia-driven target lesion revascularization; ID-TVR, ischemia-driven target vessel revascularization; MI, myocardial infarction; NA, not applicable (cannot test for heterogeneity because no events were present in 1 cell in 3 of the 4 trials); SCAI, Society for Cardiac Angiography and Interventions; TLF, target lesion failure; and TVMI, target vessel-related myocardial infarction. Reprinted with permission from Stone et al. 34 Copyright © 2016, Elsevier Ltd.
STATE OF THE ART
vice with 120-μm-thick struts. A novel DESolve scaffold (Amity), which self-corrects by up to 0.6 mm in diameter over 3 days, has been developed for use in STEMI. In conclusion, DESolve has several differentiating features compared with Absorb, and early clinical results with this device in simple lesions have been favorable. Longer-term clinical and imaging follow-up and larger experience in complex patients and lesions (ultimately including randomized trials) are required to fully characterize the DESolve scaffold and to determine its relative safety and efficacy compared with contemporary metallic DES and Absorb.
DReaMS MagNeSiuM alloy BRS
Compared with polymer-based BRSs, erodible metallic BRSs such as the magnesium-based DREAMS scaffold inherently have greater tensile strength, allowing thinner strut formulations that should reduce the profile, enhance deliverability and mechanical support, and accelerate endothelialization. Considerable iteration has occurred across 3 device generations from the absorbable magnesium stent to the DREAMS 1G and 2G scaffolds through magnesium alloy refinement and the addition of a bioresorbable polymer layer with different antiproliferative agents (Table III in the online-only Data  Supplement) . 19, 56 This evolution has prolonged the time to complete absorption from 1 to 2 months (absorbable magnesium stent) to ≈12 months (DREAMS 2G), and the progression in polymer/drug from PLGA/paclitaxel (1G) to PLLA/sirolimus (2G) has been associated with a progressive reduction in 6-month QCA in-scaffold late lumen loss from 1.08±0.49 mm (absorbable magnesium stent) to 0.65±0.50 mm (1G) to 0.44±0.36 mm (2G). The DREAMS scaffold is magnetic resonance imaging compatible, and vasomotion within the scaffolded segment in response to acetylcholine and nitrates at 6 months after percutaneous coronary intervention has been demonstrated. 19, 56, 57 A summary of studies with the different DREAMS scaffolds is shown in Table II in the online-only Data Supplement.
The current DREAMS 2G scaffold has a strut thickness ranging from 120 μm (2.5-mm diameter device) to 150 μm (3.0/3.5-mm diameter devices). Tantalum markers at the proximal and distal edges provide angiographic visualization. Sirolimus is eluted from a PLLA surface layer within ≈3 months. Magnesium absorption and scaffold dismantling are complete between 6 and 12 months. The DREAMS 2G was recently studied in 123 patients with noncomplex coronary lesions, 19 with successful implants in 121 (98.4%). At the 6-month angiographic follow-up (n=113), in-scaffold and in-segment late loss was 0.44±0.36 and 0.27±0.37 mm, respectively, and binary restenosis occurred in 6 cases (5.4%). Vasodilatation or vasoconstriction after acetylcholine or nitroglycerine administration was noted in 20 of 25 cases (80.0%). Intravascular ultrasound (n=30) showed preservation of the baseline scaffold area at 6 months. TLF occurred in 4 of 120 patients (3.3%), with no stent thromboses. 19 These early data support the clinical efficacy and safety of this device, although the angiographic in-scaffold late loss appears to be higher than that observed with Absorb or DESolve. A typical case with the DREAMS 2G scaffold is shown in Figure IV in the online-only Data Supplement.
SuMMaRy
Contemporary metallic DES are associated with very good 1-year outcomes but an ongoing hazard of very late device-related events thereafter, the pathogenesis of which is likely related to the permanent presence of a rigid metallic frame and polymer with associated incomplete healing, inflammation, neoatherosclerosis, and strut fracture. A variety of polymeric and metal-based BRSs have been developed to provide drug delivery and mechanical support functions similar to metallic DES during the first year after implantation, followed by complete resorption over 1 to 3 years with restoration of vascular structure and function, potentially improving long-term clinical outcomes (and affording other practical benefits of a nonpermanent implant). Serial multimodality imaging studies in humans have demonstrated return of cyclic pulsatility, vasomotion, and adaptive vascular responses as BRSs resorb. To date, randomized, clinical trial data are available only for the Absorb BVS and have demonstrated comparable overall 1-year clinical outcomes compared with Xience DES in simple and noncomplex lesions in patients with stable coronary artery disease and stabilized acute coronary syndrome. However, safety signals have emerged with the thickstrut first-generation device with respect to scaffold thrombosis and TVMI, especially when implanted in very small vessels, and superiority has not yet been demonstrated for BRSs compared with metallic DES. Largescale, randomized trials with 5 years of follow-up will determine whether Absorb improves very late clinical outcomes compared with Xience. Finally, compared with metallic DES, first-generation BRSs require greatfigure 4. long-term imaging after absorb bioresorbable vascular scaffold (BVS) implantation.
A short stenotic lesion in the proximal right coronary artery (RCA) was successfully treated by a 3×12-mm Absorb (white arrows). At 5 years, multislice computed tomography (MSCT) demonstrated a patent scaffolded segment (red dotted rectangle in the volume-rendering image, a). In maximal-intensity projection (B), the metallic markers at the scaffold margins remained visible as white dots on the 5-year MSCT. The MSCT was further processed for assessment of noninvasive fractional flow reserve, which demonstrated functionally nonsignificant stenosis in the proximal and distal scaffold segments (0.96 and 0.94, respectively; C). No significant stenosis was present in any major epicardial vessels (D; distal RCA, 0.86; distal left anterior descending artery, 0.92; distal left circumflex artery, 0.93). Modified with permission from Onuma et al. 49 Copyright © 2013, Elsevier, Ltd.
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er attention to procedural technique to optimize early outcomes. However, BRS devices are rapidly being iterated to improve deliverability and ease of use and to enhance safety and efficacy. a, Angiography of a mid left anterior descending artery lesion (red arrow before percutaneous coronary intervention [PCI]) in a 62-year-old woman who was treated with a 3.5×18-mm DESolve. Angiography after the procedure showed <5% residual stenosis. Follow-up (FU) at 6, 18, and 36 months is shown. The scaffolded segment (yellow arrows) was patent at each time point. A slight reduction in lumen diameter was observed at 6 months, with no significant further changes over time. B, OCT images from after the procedure to 36 months. The proximal metallic scaffold marker (red circles) is used for coregistration. After the procedure, the square, low-intensity struts are well apposed to the vessel wall, demonstrating adequate and circumferential expansion. In-scaffold plaque dissection is seen at 11 o'clock. At 6 months, the struts are fully encapsulated by neointimal tissue. An 11% increase in scaffold area accommodated most neointimal tissue formation, resulting in a slight net reduction in lumen dimensions. At 18 months, the lumen area is preserved and more concentric. Polymeric material is not likely present at this time; the strut voids are filled with a proteoglycan matrix. At 36 months the extracellular matrix is replaced by dense connective tissue, and strut voids are no longer visible. The only remnant of the original scaffold is the permanent metallic marker. Lumen dimensions are preserved, and homogeneous, high-backscattering vascular tissue is evident. Courtesy of Alex Abizaid and Daniel Chamié. 
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